Tango Therapeutics Inc
NASDAQ:TNGX
Tango Therapeutics Inc
NASDAQ:TNGX
Price:
17.3
USD
0.87%
Market Closed
Market Cap:
$2.3B
Income Statement
Earnings Waterfall
Tango Therapeutics Inc
Tango Therapeutics Inc
Income Statement
Tango Therapeutics Inc
Tango Therapeutics Inc
Currency: USD
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Revenue |
25
N/A
|
31
+28%
|
37
+18%
|
43
+16%
|
24
-44%
|
24
+1%
|
25
+3%
|
25
+0%
|
34
+36%
|
38
+11%
|
37
-3%
|
37
+2%
|
43
+14%
|
43
+2%
|
42
-3%
|
41
-3%
|
24
-41%
|
67
+174%
|
62
-6%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(41)
|
(68)
|
(95)
|
(126)
|
(116)
|
(127)
|
(136)
|
(141)
|
(148)
|
(147)
|
(151)
|
(164)
|
(175)
|
(183)
|
(188)
|
(186)
|
(182)
|
(177)
|
(174)
|
|
| Selling, General & Administrative |
(7)
|
(12)
|
(18)
|
(24)
|
(25)
|
(28)
|
(30)
|
(31)
|
(33)
|
(34)
|
(36)
|
(38)
|
(40)
|
(42)
|
(44)
|
(45)
|
(45)
|
(43)
|
(42)
|
|
| Research & Development |
0
|
(22)
|
(78)
|
(68)
|
(92)
|
(98)
|
(106)
|
(110)
|
(115)
|
(113)
|
(115)
|
(125)
|
(135)
|
(141)
|
(144)
|
(142)
|
(136)
|
(134)
|
(132)
|
|
| Other Operating Expenses |
(34)
|
(34)
|
0
|
(34)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(17)
N/A
|
(36)
-116%
|
(58)
-60%
|
(83)
-43%
|
(92)
-11%
|
(102)
-11%
|
(111)
-8%
|
(116)
-4%
|
(114)
+2%
|
(110)
+4%
|
(114)
-4%
|
(126)
-10%
|
(133)
-5%
|
(140)
-5%
|
(146)
-4%
|
(146)
0%
|
(157)
-7%
|
(110)
+30%
|
(111)
-1%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
5
|
7
|
8
|
8
|
8
|
8
|
7
|
6
|
6
|
6
|
|
| Total Other Income |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
1
|
3
|
4
|
5
|
6
|
7
|
8
|
8
|
8
|
7
|
5
|
4
|
4
|
|
| Pre-Tax Income |
(17)
N/A
|
(36)
-117%
|
(58)
-60%
|
(83)
-43%
|
(91)
-10%
|
(101)
-10%
|
(108)
-7%
|
(111)
-3%
|
(107)
+4%
|
(100)
+6%
|
(102)
-2%
|
(112)
-10%
|
(116)
-4%
|
(123)
-6%
|
(130)
-6%
|
(132)
-1%
|
(145)
-11%
|
(100)
+31%
|
(102)
-1%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(17)
|
(36)
|
(58)
|
(83)
|
(92)
|
(101)
|
(108)
|
(111)
|
(107)
|
(100)
|
(102)
|
(112)
|
(117)
|
(124)
|
(130)
|
(133)
|
(146)
|
(101)
|
(102)
|
|
| Net Income (Common) |
(17)
N/A
|
(36)
-117%
|
(58)
-61%
|
(83)
-43%
|
(92)
-10%
|
(101)
-10%
|
(108)
-7%
|
(111)
-3%
|
(107)
+4%
|
(100)
+6%
|
(102)
-2%
|
(112)
-10%
|
(117)
-5%
|
(124)
-6%
|
(130)
-5%
|
(133)
-2%
|
(146)
-10%
|
(101)
+31%
|
(102)
-1%
|
|
| EPS (Diluted) |
-0.16
N/A
|
-0.51
-219%
|
-0.94
-84%
|
-0.94
N/A
|
-1.04
-11%
|
-1.15
-11%
|
-1.23
-7%
|
-1.26
-2%
|
-1.21
+4%
|
-1.03
+15%
|
-1.08
-5%
|
-1.03
+5%
|
-1.08
-5%
|
-1.15
-6%
|
-1.19
-3%
|
-1.21
-2%
|
-1.32
-9%
|
-0.85
+36%
|
-0.87
-2%
|
|
Switch to:
Switch to:
See Also
Discover More
